Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $1.4 million.

  • CytomX Therapeutics' Goodwill & Intangibles fell 930.53% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 930.53%. This contributed to the annual value of $1.5 million for FY2024, which is 870.08% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Goodwill & Intangibles is $1.4 million, which was down 930.53% from $1.5 million recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Goodwill & Intangibles high stood at $2.1 million for Q1 2021, and its period low was $1.4 million during Q3 2025.
  • Moreover, its 5-year median value for Goodwill & Intangibles was $1.8 million (2023), whereas its average is $1.8 million.
  • Per our database at Business Quant, CytomX Therapeutics' Goodwill & Intangibles plummeted by 656.18% in 2021 and then plummeted by 930.53% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Goodwill & Intangibles (Quarter) stood at $2.0 million in 2021, then fell by 7.41% to $1.8 million in 2022, then decreased by 8.0% to $1.7 million in 2023, then decreased by 8.7% to $1.5 million in 2024, then fell by 7.11% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.5 million for Q2 2025, and $1.5 million during Q1 2025.